



FACULDADE DE MEDICINA  
UNIVERSIDADE DO PORTO

**MESTRADO INTEGRADO EM MEDICINA**

---

2014/2015

Daniel Artur Abreu Martins

**GABA-Dependent Pain Facilitation of Spinal 5-HT<sub>3</sub>R  
In Diabetic Neuropathic Pain**

março, 2015

FMUP



FACULDADE DE MEDICINA  
UNIVERSIDADE DO PORTO

Daniel Artur Abreu Martins

**GABA-Dependent Pain Facilitation of Spinal 5-HT<sub>3</sub>R  
in Diabetic Neuropathic Pain**

**Mestrado Integrado em Medicina**

**Área: Neurociências**

**Trabalho efetuado sob a Orientação de:**

**Doutora Carla Sofia Costa Morgado**

**E sob a Coorientação de:**

**Doutora Isaura Ferreira Tavares**

**Trabalho organizado de acordo com as normas da revista:**

***European Journal of Pain***

março, 2015

**FMUP**

Eu, Daniel Artur Abreu Martins, abaixo assinado, nº mecanográfico 200908272, estudante do 6º ano do Ciclo de Estudos Integrado em Medicina, na Faculdade de Medicina da Universidade do Porto, declaro ter atuado com absoluta integridade na elaboração deste projeto de opção.

Neste sentido, confirmo que **NÃO** incorri em plágio (ato pelo qual um indivíduo, mesmo por omissão, assume a autoria de um determinado trabalho intelectual, ou partes dele). Mais declaro que todas as frases que retirei de trabalhos anteriores pertencentes a outros autores, foram referenciadas, ou redigidas com novas palavras, tendo colocado, neste caso, a citação da fonte bibliográfica.

Faculdade de Medicina da Universidade do Porto, 03/03/2015

Assinatura conforme cartão de identificação:

Daniel Artur Abreu Martins

NOME

Daniel Artur Abreu Martins

CARTÃO DE CIDADÃO OU PASSAPORTE (se estrangeiro)

E-MAIL

TELEFONE OU TELEMÓVEL

13905060

Daniel\_artur@hotmail.com

912331662

NÚMERO DE ESTUDANTE

DATA DE CONCLUSÃO

200908272

Julho, 2015

DESIGNAÇÃO DA ÁREA DO PROJECTO

Neurociências

TÍTULO DISSERTAÇÃO

GABA-Dependent Pain Facilitation of Spinal 5-HT<sub>3R</sub> in Diabetic Neuropathic Pain

ORIENTADOR

Carla Sofia Costa Morgado

COORIENTADOR (se aplicável)

Isaura Ferreira Tavares

É autorizada a reprodução integral desta Dissertação para efeitos de investigação e de divulgação pedagógica, em programas e projectos coordenados pela FMUP.

Faculdade de Medicina da Universidade do Porto, 03/03/2015

Assinatura conforme cartão de identificação: Daniel Artur Abreu Martins

*À Professora Doutora Carla Morgado,  
por tudo quanto me ensinou e permitiu que aprendesse sozinho.*

*À Professora Doutora Isaura Tavares,  
pelas palavras de encorajamento e pelos desafios constantes.*

*À Mestre Marta Silva,  
a companheira de todas as horas.*

*A todos os elementos do Departamento de Biologia Experimental,  
uma segunda família.*

*À minha família,  
pelo suporte e dedicação.*

*À Nádia,  
pelas muitas conversas de janela.*

*A todos os meus amigos,  
pelo carinho, companheirismo e gargalhadas.*

# **GABA-Dependent Pain Facilitation of Spinal 5-HT3R In Diabetic Neuropathic Pain**

**Running title:** 5-HT3R pronociception in diabetic neuropathic pain

M Silva\*, D Martins\*, I Tavares, C Morgado

Instituto de Investigação e Inovação em Saúde, Universidade do Porto,  
Portugal

IBMC, Instituto de Biologia Molecular e Celular, Universidade do Porto,  
Portugal

Departamento de Biologia Experimental, Faculdade de Medicina do Porto,  
Universidade do Porto, Portugal

\* The authors contributed equally to the manuscript

## **Corresponding author:**

Carla Morgado  
Department of Experimental Biology  
Faculty of Medicine of Porto  
Alameda Prof. Hernâni Monteiro  
4200-319 Porto  
Portugal  
Fax: +351225513655  
Phone: +351225513654  
e-mail: [cmorgado@med.up.pt](mailto:cmorgado@med.up.pt)

## **Category of manuscript**

original article

## **Funding sources**

Supported by FPF7 EU Project REDDSTAR (FP7-Health-2012.2.4.3-1)

## **Conflict of interests**

The authors declare no conflict of interests

### **What's already known about this topic?**

- Activation of 5-HT<sub>3</sub> receptors expressed in GABAergic neurons of the spinal cord increases GABA release
- Inhibition of spinal 5-HT<sub>3</sub>R decreases pain hypersensitivity in animal models of chronic inflammatory and traumatic neuropathic pain

### **What does this study add?**

- Spinal 5-HT<sub>3</sub> receptors facilitate pain transmission and contributes to ERKs-mediated spinal sensitization during diabetic neuropathy
- 5-HT<sub>3</sub>R-mediated pain facilitation during DNP is dependent on spinal GABAergic post-synaptic neurotransmission

## **Abstract**

**Background:** Spinal 5-HT<sub>3</sub> receptors (5-HT<sub>3</sub>R) has been implicated in chronic pain development. The extent to which 5-HT<sub>3</sub>R contributes to spinal sensitization and pain during diabetic neuropathy (DN) remain elusive and the mechanisms subserving the effects of 5-HT<sub>3</sub>R activation on spinal pain processing are still unclear. This study aimed to evaluate the contribution of spinal 5-HT<sub>3</sub>R to pain facilitation and spinal sensitization during DN. Moreover, considering the pain facilitation mediated by spinal GABA in DN and the increased release of GABA upon 5-HT<sub>3</sub>R activation, the role of GABA as a mediator of 5-HT<sub>3</sub>R spinal effect was assessed.

**Methods:** Mechanical nociception was evaluated by paw pressure test in streptozotocin (STZ)-diabetic and control rats after intrathecal (i.t.) administration of 5-HT<sub>3</sub>R antagonist (Y25130). The spinal activation of extracellular signal-regulated kinases (ERKs) pathway and the expression of 5-HT<sub>3</sub>R, glial fibrillary acidic protein (GFAP; marker of astroglia activation) and ionized calcium binding adaptor molecule 1 (IBA-1; marker of microglia activation) were evaluated at the peak maximum effect of Y25130. The involvement of GABA in the behavioural pain effect of Y25130, was assessed in STZ-diabetic animals receiving i.t. administrations of muscimol (GABA<sub>A</sub>R agonist).

**Results:** Intrathecal administration of Y25130 reverted mechanical hyperalgesia and ERK-mediated spinal sensitization in STZ-diabetic rats, while no effects were observed in control animals. The spinal activation of GABA<sub>A</sub>R by i.t. administration of muscimol abolished Y25130-driven antinociception. The expression of IBA-1, GFAP and 5-HT<sub>3</sub>R was unaltered by treatment.

**Conclusion:** These findings point for a GABA-dependent pronociceptive role of spinal 5-HT<sub>3</sub>R in this chronic pain condition.

**Key-Words:** Diabetic neuropathic pain; 5-HT<sub>3</sub>R; GABA; Pain facilitation; ERK1/2, spinal sensitization

## 1. Introduction

Diabetic neuropathic pain (DNP) is a debilitating complication of diabetes characterized by spontaneous pain, mechanical hyperalgesia and tactile allodynia (Galer et al., 2000). DNP have been mostly attributed to damage of peripheral nerves (Chen and Levine, 2001), however several studies have showed that functional impairments in spinal nociceptive processing account for pain during diabetes (Pertovaara et al., 2001; Chen and Pan, 2002; Morgado and Tavares, 2007; Morgado et al., 2010).

Functional studies using the streptozotocin (STZ)-diabetic rat showed that impaired pain responses are accompanied by spontaneous hyperactivity and hyperexcitability of nociceptive spinal circuits (Morgado and Tavares, 2007; Li et al., 2010). These changes have been attributed to increased peripheral input and recruitment of nociceptive ascending pathways (Burchiel et al., 1985; Chen and Pan, 2002), to alterations of spinal nociceptive modulatory mechanisms (Morgado et al., 2008) and, more recently, to impairments in pain modulation from supraspinal areas (Paulson et al., 2007; Morgado et al., 2011b; Silva et al., 2013). Recent studies showed that the behavioral hypersensitivity and spinal neuronal hyperexcitability are accompanied by persistent activation of descending pain circuits (Morgado et al., 2011b; Silva et al., 2013), namely the descending serotonergic pathways arising from the rostroventromedial medulla (RVM) (Morgado et al., 2011b). The RVM is a key brainstem relay station of the descending pain modulatory circuits, which modulates spinal pain transmission mainly by the release of serotonin. Depending on the receptor subtype activated and the pain condition serotonin can inhibit or enhance spinal nociceptive transmission (Dogrul et al., 2009). The 5-HT<sub>3</sub> receptors (5-HT<sub>3</sub>R), the only 5-HT ionotropic receptor with excitatory functions, are expressed in the spinal dorsal horn neurons and in the central terminals of primary afferents (Kia et al., 1995). Experimental data on 5-HT<sub>3</sub>R-mediated modulation of spinal nociceptive processing during acute pain seem conflicting, with studies dividing between anti- and pronociceptive roles (Alhaider et al., 1991; Guo et al., 2014). A pain facilitatory role of spinal 5-HT<sub>3</sub>R has been demonstrated in animal models of chronic inflammatory and traumatic neuropathic pain (Rahman et al., 2009;

Kim et al., 2014) .

The mechanisms contributing to spinal 5-HT<sub>3</sub>R-mediated pain modulation remain elusive. Studies developed in healthy animals, demonstrated that 5-HT<sub>3</sub>R activation enhances spinal GABA release, which by acting on GABA receptors inhibits nociceptive transmission and accounts to the attenuated behavioral responses observed after 5HT<sub>3</sub>R agonist intrathecal administration (Alhaider et al., 1991). However, it should be noted that chronic pain, including DNP, is accompanied by a shift in spinal GABA role, which was shown to exert excitatory instead of inhibitory effects when activating the post-synaptic ionotropic GABA<sub>A</sub> receptor (GABA<sub>A</sub>R) (Jolivalt et al., 2008; Morgado et al., 2008). We hypothesized that GABA release induced by 5-HT<sub>3</sub>R activation may be eliciting pro-nociceptive effects during DNP, contributing to pain facilitation.

We used the STZ-diabetic rat, a rodent model widely used to study DNP (Calcutt, 2004), to: i) evaluate the contribution of spinal 5-HT<sub>3</sub>R to pain facilitation and spinal sensitization during DNP; ii) evaluate the involvement of GABA on spinal 5-HT<sub>3</sub>R-mediated effects on pain modulation in DNP.

## **2. Material and Methods**

### **2.1. Animals**

Male Wistar rats (Charles River, France), weighting 250-350g at the beginning of the experiments were used. The animals were housed 1 per cage with corncob bedding, in a room with controlled environmental conditions (temperature, 22 ± 2°C; humidity, 55 ± 5%) under a 12-h light/dark cycle (lights on from 8 am to 8 pm). Food (diet ref: A04, SAFE) and water were available ad libitum. The experiments were licensed by the Portuguese Food and Veterinary General Directorate (licence number 0420/000/000/2012) and were performed in accordance with the ethical guidelines of the European Community Council Directive 2010/63/EU and of the International Association for the Study of Pain in conscious animals (Zimmermann, 1983).

## **2.2. Induction of diabetes**

Animals were made diabetic by a single intraperitoneal (i.p.) injection of STZ (60 mg/kg body weight; Sigma-Aldrich, Spain). Age-matched controls received equal volume of vehicle solution (citrate buffer 0.1M, pH 4.5). Three days after STZ-injection, glucose concentration was measured in blood samples collected from the tail vein using BREEZE<sup>®</sup> 2 blood glucose monitoring system (Bayer Diabetes Care, USA). Only rats with blood glucose concentration higher than 270 mg/dl were considered diabetic and included in the STZ group. At the sacrifice, blood samples were collected for the quantification of plasma glucose (BREEZE<sup>®</sup> 2, Bayer Diabetes Care, USA) and hemoglobin A1C levels (A1CNow+<sup>®</sup>, Bayer Diabetes Care, USA).

## **2.3. Catheter implantation**

Three weeks after diabetes induction, a silicon catheter was implanted into the lumbar subarachnoid space for intrathecal (i.t.) administrations. Animals were deeply anaesthetised with a mixture of ketamine and medetomidine (75 mg/kg of ketamine and 1mg/kg of medetomidine, i.p). Anesthesia was maintained during the surgical procedure with controlled levels of volatile anesthetic (isoflurane; 0.5-2%) in 60% oxygen/air mixture. A laminectomy was performed at T8 –T9 levels and a sterile silicone catheter (length: 13cm, inside diameter: 0.31mm, outside diameter: 0.64mm) (60-011-01; Helix Medical Europe SE & Co.KG, Germany) was introduced into the subarachnoid space and advanced 2.5–3 cm caudally, until the tip of the catheter was positioned at L4 – L5 spinal levels. The other end of the intrathecal catheter was sealed, externalized and fixed to the back of the neck. Animals were allowed to recover for a week. At the end of experiments, during the dissection procedure, the position of the catheter tip was verified and only the animals with the catheter correctly positioned at L4 – L5 levels were included in the study.

## **2.4. Behavioural evaluation of mechanical nociception**

Four weeks after diabetes induction, mechanical nociception was evaluated by paw-pressure test (Randall-Selitto test, Ugo-Basile, Comerio, Italy) in STZ-diabetic and age-matched control rats receiving intrathecal infusions of saline (n=5) or the 5-HT<sub>3</sub>R antagonist (Y-25130 hydrochloride, n=5) in a dose of 30 fmol. The selection of 5-HT<sub>3</sub>R antagonist and respective dose was performed in accordance with a previous study using the same administration route (Guo et al., 2014). The mechanical force, in grams, that induced hindpaw withdrawal was recorded before intrathecal injection, at 30 min, 2h, 4h, 6h and 24h post injection. A 25 µl Hamilton syringe was attached to the silicon catheter and 25 µl of saline or 5-HT<sub>3</sub>R antagonist was slowly injected, followed by a flushing with saline to guarantee that all the solution was injected. Intrathecal injections were performed under light anaesthesia (1.5-3% isoflurane in 60% oxygen/air mixture).

In order to evaluate GABA involvement in 5-HT<sub>3</sub>R mediated pain modulation, additional groups of STZ-diabetic animals received intrathecal administrations of Y25310 (n=5) or saline (n=5), followed by an intrathecal administration of the GABA<sub>A</sub> receptor agonist muscimol (0.3 µg), 30 min before the maximum peak effect of Y25310 (3.5 h after Y25310 or saline administration). The mechanical nociception was evaluated 30 min after muscimol injection. A 10 µl Hamilton syringe was attached to the silicon catheter and 10 µl of muscimol was slowly injected, followed by flushing with saline to guarantee that all the solution was completely delivered. The dose of intrathecal muscimol used was chosen in accordance with previous studies using the same administration route (Hwang and Yaksh, 1997; Jolivalt et al., 2008).

## **2.5. Immunohistochemistry**

To evaluate the effects of 5-HT<sub>3</sub>R on spinal sensitization, additional groups of control and STZ-diabetic animals were treated with saline or Y-25130 hydrochloride, as described in 2.4, and sacrificed at the time-point showing the maximum effect of treatment. The animals were deeply

anaesthetized with a ketamine/medetomidine mixture (75 mg/kg of ketamine and 1mg/kg of medetomidine, i.p) and transcardially perfused with 250 ml of calcium free Tyrode's solution, followed by 1000 ml of 4% paraformaldehyde in 0.1 M phosphate buffer pH 7.4 (PFA). The spinal segments L4–L5 were removed, post-fixed in 4% PFA for 2–4h and transferred to 30% sucrose in 0.1 M PBS overnight at 4 °C. Coronal sections, 40 µm thick, were obtained using a freezing microtome. One in each 4 sections was immunoreacted against the subunit A of 5-HT3 receptor (5-HT3RA) or phosphorylated extracellular signal-regulated kinases 1 and 2 (pERK1/2, marker of nociceptive activity) (Ji et al., 1999), using the avidin–biotin–peroxidase method. The sections were initially treated with 1% hydrogen peroxidase for 20 min in order to inhibit the activity of endogenous peroxidase followed by an incubation period of 2h in a blocking solution of 10% normal horse serum (NHS) in 0.3% Triton X 25% in PBS (PBST) with 0.1 M glycine. The sections were then incubated two overnights at 4°C in goat anti-5HT3RA (1:250; ref: AP16518PU-N; Acris Antibodies) or mouse anti-pERK1/2 (1:1000; ref: ab50011; Abcam) primary antibodies diluted in PBST with 2% NHS. After being washed in PBST with 2% NHS, the sections were incubated in biotinylated horse anti-goat immunoglobulin for 5-HT3RA (Vector Laboratories) and horse anti-mouse immunoglobulin for pERK1/2 (Vector Laboratories), all diluted at 1:200 in PBST with 2% NHS, for 1h, at room temperature. Sections were then washed in PBST, incubated for 1 h in the avidin–biotin complex (Vectastain, Vector Laboratories), and stained with diaminobenzidine (10 mg diaminobenzidine in 20 ml of Tris–HCl 0.05 M, pH 7.6 solution with 5 µl of 30% hydrogen peroxide). Sections were mounted on gelatin-coated slides, air-dried, and coverslipped with Eukit medium. Photomicrographs of sections were obtained by using an optical light microscope coupled with a high-resolutions digital camera (Axioskop 40; Zeiss, Hertfordshire, UK). Acquisition conditions (objective amplification, light intensity, contrast and hue) were maintained constant in all photomicrographs captions. The 5-HT3RA expression levels were quantified bilaterally in lamina I–V by immunolabelling densitometric analysis (6–8 sections per animal; n=4 per experimental group), using Image J software. For pERK1/2 quantification the numbers of pERK1/2-immunoreactive (pERK1/2-IR) cells were counted

bilaterally in laminae I–V (9-10 sections per animal; n=3-5 *per* experimental group). Delamination of the spinal cord was performed according to The Rat Brain Atlas (Paxinos and Watson, 2007). All analysis were performed by a blinded experimenter.

## 2.6. Western Blotting

For western blot experiments, control and STZ-diabetic animals received intrathecal infusions of saline or Y-25130 hydrochloride, as described in 2.4, and were sacrificed by decapitation under deep anaesthesia (75 mg/kg of ketamine and 1mg/kg of medetomidine, i.p) at the peak maximum Y25130 effects (n=3-5 *per* experimental group). The spinal L4-L5 segments were immediately removed and frozen at -80 °C. The spinal segments were then homogenized in a lysis buffer (20 mM MOPS, pH 7.0, 2 mM EGTA, 5 mM EDTA, 1% Triton X-100) enriched with proteinase and phosphatase inhibitor cocktails (1:100; Sigma-Aldrich). Homogenates were centrifuged at 21100g for 20 min at 4 °C and the supernatants were collected. The protein concentration was quantified using Bradford Assay (Bradford Reagent; ref: #500-0205; Bio-Rad), using serial diluted bovine serum albumin (BSA) solutions as standards. Samples were heated at 100°C for 5 min and 50µg protein of each sample was loaded onto 12% SDS-polyacrylamide gel, separated by electrophoresis and transferred to nitrocellulose membranes. The membranes were blocked in 5% BSA for 1 h and incubated overnight at 4°C with mouse anti-pERK1/2 (1:5000; ref: ab50011; Abcam), rabbit anti-ERK1/2 (1:1000, ref: 04/2010; Cell Signalling Technology), goat anti-5HT3RA (1:500; ref: AP16518PU-N; Acris Antibodies), mouse anti- $\alpha$ -Tubulin (1:10000; ref: T5168; Sigma-Aldrich), mouse anti-gial fibrillary acidic protein (GFAP) (1:1000; ref: G3893; Sigma-Aldrich), rabbit anti-ionized calcium binding adaptor molecule 1 (IBA1) (1:1000; ref: 019-19741; Wako) and rabbit anti- $\beta$ -Actin (1:1000; ref: sc-130657; Santa Cruz Biotechnology) primary antibodies. The membranes were washed and incubated for 1h in horseradish peroxidase-conjugated secondary antibodies anti-mouse for pERK1/2, GFAP and  $\alpha$ -Tubulin (1:10000; ref: NA931VS; Amersham), anti-goat for 5HT3RA (1:10000; ref: sc-2020, Santa Cruz Biotechnology) or anti-rabbit for IBA-1 and

$\beta$ -Actin (1:10000; ref: NA934VS; Amersham). The pERK1/2/total ERK1/2 ratio was calculated to determine the phosphorylated fraction of ERKs. The signal was detected using a sensitive chemiluminescence reagent (Clarity Western ECL, ref: #170-5061; Bio-Rad). The GFAP and IBA-1 expression was used as astroglia and microglia markers, respectively (Ohsawa et al., 2004; Brahmachari et al., 2006). The  $\alpha$ -Tubulin and  $\beta$ -actin were used as internal standards. Images were captured using a ChemiDoc XRS system (Bio-Rad) and the densitometric analysis of the bands was performed using Image Lab 5.1 software (Bio-Rad).

## **2.7. Drugs**

Streptozotocin was purchased from Sigma-Aldrich, Spain. 5-HT<sub>3</sub>R antagonist Y-25130 hydrochloride and GABA<sub>A</sub> receptor agonist muscimol were purchased from TOCRIS Bioscience, UK.

## **2.8. Antibodies specificity**

The specificity of each primary antibody was previously demonstrated (Kanazawa et al., 2002; Ralph et al., 2006; Wang and Hatton, 2009; Fei et al., 2011; Kaur and Tikoo, 2013; Uslu et al., 2014). Control experiments were performed by omission of primary or secondary antibodies. Additionally, for western blot experiments, the specificity of the primary antibodies was demonstrated by the detection of bands in the expected molecular weight.

## **2.9. Statistical analysis**

The statistical analysis of data was performed using GraphPad PRISM version 6.0. The results of the behavioral evaluation of the effects of intrathecal administration of Y25130 on mechanical nociception were compared using two-way analysis of variance (ANOVA) repeated measures, followed by Tukey post-hoc test for multiple comparisons. The results of the behavioral evaluation of the effects of muscimol and of immunohistochemistry and the western blots experiments were compared using one-way ANOVA,

followed by Tukey post-hoc test for multiple comparisons. Independent sample t-test was used to compare metabolic parameters and pretreatment behavioral data between STZ and control animals. Statistical significance was settled at  $p < 0.05$ . Results are expressed as mean  $\pm$  standard error of the mean (s.e.m.).

### **3. Results**

#### **3.1. Metabolic characterization**

Four weeks after the induction of diabetes, STZ-diabetic rats presented significantly increased blood glucose concentration (STZ:  $512.19 \pm 10.15$  mg/dL; control:  $121.3 \pm 7.36$  mg/dL;  $p < 0.0001$ ) and hemoglobin A1C levels (STZ:  $12.1 \pm 0.25\%$ ; control:  $4.8 \pm 0.06\%$   $p < 0.0001$ ), along with decreased body weights (STZ:  $261.5 \pm 6.55$  g; control:  $402.1 \pm 5.98$  g;  $p < 0.0001$ ), when compared with age-matched control animals (Table S1), which is in accordance with previous reports using the same animal model (Courteix et al., 1993; Calcutt, 2004; Morgado and Tavares, 2007) and support the installation of diabetes.

#### **3.2. Effect of i.t. administration of 5-HT<sub>3</sub>R antagonist on mechanical nociception**

Four weeks after diabetes onset, STZ-diabetic rats developed mechanical hyperalgesia (Fig 1) , as demonstrated by the significantly lower pretreatment paw withdrawal threshold (PWT) of STZ-diabetic animals when compared with control animals (STZ:  $59.8 \pm 3.77$  g; control:  $103.0 \pm 2.49$  g;  $p < 0.0001$ ). Intrathecal delivery of Y25130 significantly increased the PWT in STZ-diabetic rats, showing an antinociceptive effect of Y25130 during DNP. The antinociceptive effects of Y25130 in STZ-diabetic animals were evident at 0.5h (STZ+Saline:  $59.8 \pm 5.05$  g; STZ+Y25130:  $88.4 \pm 2.26$  g;  $p < 0.001$ ) and had a maximum peak at 4h (STZ+Saline:  $61.0 \pm 3.22$  g; STZ+Y25130:  $109.8 \pm 7.39$  g;  $p < 0.0001$ ), returning to pretreatment values 6h post-administration (STZ+Y25130 pretreatment:  $62.2 \pm 3.38$  g; STZ+Y25130:  $71.4 \pm 3.29$  g;  $p >$

0.05). The administration of Y25130 had no effect in the mechanical response thresholds of control rats in any time-point evaluated (control+Y25130 pretreatment:  $101.8 \pm 4.80$  g; control+Y25130 at 0.5h post-injection:  $96.6 \pm 9.22$  g, control+Y25130 at 4h post-injection:  $102.8 \pm 6.62$ , control+Y25130 at 6h post-injection:  $95.2 \pm 4.55$  g;  $p > 0.05$ ) (Fig 1).

### **3.3. Effect of i.t. administration of 5-HT<sub>3</sub>R antagonist on spinal ERK1/2 activation**

The STZ-diabetic rats receiving saline infusions presented a significantly higher number of pERK1/2- IR cells when compared with control animals (STZ+Saline:  $657.9 \pm 37.42$ ; control+Saline:  $306.9 \pm 58.63$ ,  $p < 0.01$ ) (Fig 2). Administration of Y25130 to STZ-diabetic animals significantly reduced spinal ERK1/2 activation (Fig 2), as demonstrated by the significantly lower number of pERK1/2-IR cells observed in the spinal sections of Y25130-treated STZ-animals (STZ+Saline:  $657.9 \pm 37.42$ ; STZ+Y25130:  $417.0 \pm 41.27$ ,  $p < 0.05$ ) (Fig 2a and c-f). The treatment had no effects in the number of pERK1/2-IR cells in the spinal cord of control rats (control+Saline:  $306.9 \pm 58.63$ ; control+Y25130:  $293.1 \pm 44.67$ ,  $p > 0.05$ ). Western blotting quantification of pERK1/2 and ERK1/2 expression in spinal homogenates from STZ-diabetic and control animals treated with saline or Y25130 also showed that administration of Y25130 significantly reduced spinal ERK1/2 activation in STZ-diabetic rats, as demonstrated by the significantly lower phosphorylated fraction of ERK1/2 content in STZ-diabetic rats treated with Y25130 (STZ+Saline:  $4.0 \pm 1.00$ ; STZ+Y25130:  $1.2 \pm 0.49$ ; control+Saline:  $1.5 \pm 0.05$ ; control+Y25130:  $1.2 \pm 0.34$ ,  $p < 0.05$ ) (Fig 2b).

### **3.4. Effect of i.t. administration of 5-HT<sub>3</sub>R antagonist on spinal glia activation**

In order to evaluate if spinal 5-HT<sub>3</sub>R antagonism during DNP interferes with glia activity, we evaluate the effect of spinal 5-HT<sub>3</sub>R inhibition on spinal GFAP and IBA-1 expression levels. The expression of GFAP was significantly lower in STZ-diabetic rats than in controls animals (STZ+Saline:  $0.04 \pm 0.012$ ;

control+Saline:  $0.92 \pm 0.085$ ;  $p < 0.01$ ) (Fig S1b and c). The expression levels of IBA-1 were significantly higher in STZ-animals when compared with control rats (STZ+Saline:  $1.9 \pm 0.08$ ; control+Saline:  $1.1 \pm 0.05$ ;  $p < 0.01$ ) (Fig S1a and c). The spinal 5-HT3R inhibition did not affect the expression levels of GFAP (STZ+Saline:  $0.04 \pm 0.012$ ; STZ+Y25130:  $0.04 \pm 0.006$ ;  $p > 0.05$ ; control+Saline:  $0.92 \pm 0.085$ ; control+Y25130:  $0.96 \pm 0.21$ ,  $p > 0.05$ ) and IBA-1 (STZ+Saline:  $1.9 \pm 0.08$ ; STZ+Y25130:  $1.8 \pm 0.12$ ;  $p > 0.05$ ; control+Saline:  $1.1 \pm 0.05$ ; control+Y25130:  $1.2 \pm 0.12$ ;  $p > 0.05$ ), neither in STZ-diabetic nor in control rats (Fig S1).

### **3.5. Expression of 5-HT3RA at the spinal dorsal horn**

Since 5-HT3R inhibition had differential effects on nociceptive responses of STZ-diabetic and control animals, we hypothesized that the selective 5-HT3R-mediated pain facilitation during DNP could be explained by a possible change in the expression of the receptor induced by diabetes. Densitometric immunolabelling analysis of spinal 5-HT3RA expression did not reveal significant differences between the STZ-diabetic and control rats (STZ+Saline:  $46.0 \pm 1.90$ ; STZ+Y25130:  $39.8 \pm 2.92$ ; control+Saline:  $40.6 \pm 4.77$ ; control+Y25130:  $43.6 \pm 2.94$ ;  $p > 0.05$ ) (Fig S2a and c-f). These findings were corroborated by western blotting analysis of the receptor expression (STZ+Saline:  $0.3 \pm 0.08$ ; STZ+Y25130:  $0.5 \pm 0.14$ ; control+Saline:  $0.3 \pm 0.02$ ; control+Y25130:  $0.4 \pm 0.12$ ;  $p > 0.05$ ) (Fig S2b).

### **3.6. Effect of i.t. administration of GABA<sub>A</sub>R agonist on the effect of spinal 5-HT3R inhibition**

Muscimol administration prevented the antinociceptive effect elicited by 5-HT3R inhibition in STZ-diabetic rats, as showed by the reduction in PWT to levels of pretreatment in muscimol+Y25130-treated STZ-animals (STZ+Y25130 pretreatment:  $60.6 \pm 2.46$  g; STZ+Y25130 at 4h post-injection:  $109.8 \pm 7.39$  g; STZ+Y25130+Muscimol at 4h post-injection:  $57.0 \pm 6.43$  g,  $p < 0.001$  in STZ+Y25130 at 4h post-injection vs the other groups) (Fig 3). Muscimol had no effects in the mechanical response thresholds of STZ-

diabetic animals receiving saline infusions (STZ+Saline pretreatment:  $61.0 \pm 3.22$  g; STZ+Saline+Muscimol at 4h post-saline injection:  $56.0 \pm 7.10$  g,  $p > 0.05$ ) (Fig 3).

## Discussion

By using a pharmacological approach to inhibit the 5-HT<sub>3</sub>R at the spinal cord in a validated model of DNP, the present study is the first to demonstrate that spinal 5-HT<sub>3</sub>R activation is involved in pain facilitation and contributes to spinal sensitization through the activation of ERK1/2 pathways during DNP. The present study also provides new insights into the mechanisms underlying 5-HT<sub>3</sub>R-spinal nociceptive modulation in chronic pain by showing that 5-HT<sub>3</sub>R pronociception is mediated by spinal GABAergic signalling.

The development of persistent pain appears to be dependent, in part, upon increased drive of RVM-arising 5-HT descending pathways, which leading to activation of 5-HT<sub>3</sub>R at the spinal level, seems to facilitate pain transmission during chronic pain (Suzuki et al., 2002; Dogrul et al., 2009). The pain behavior detected in the second-phase of the formalin test, but not that observed in the first-phase, has been reported to be significantly reduced in mice lacking the subunit A of 5-HT<sub>3</sub>R and in animals receiving intrathecal administrations of 5-HT<sub>3</sub>R antagonists, suggesting an involvement of 5-HT<sub>3</sub>R in pain chronification (Oyama et al., 1996; Zeitz et al., 2002). However, some contradictory evidences exist in what concern the role of spinal 5-HT<sub>3</sub>R in pain modulation, with studies demonstrating that spinal 5-HT<sub>3</sub>R elicits antinociceptive effects in acute pain (Glaum et al., 1990; Alhaider et al., 1991). These findings point for a possible shift in the role of spinal 5-HT<sub>3</sub>R in chronic pain conditions. Our data show that inhibition of spinal 5-HT<sub>3</sub>R by intrathecal administration of a selective 5-HT<sub>3</sub>R antagonist reverted the mechanical hyperalgesia in STZ-diabetic rats. Previous studies using STZ-diabetic rats reported an increased activation of serotonergic neurons at the RVM along with higher spinal serotonin contents during DNP (Morgado et al., 2011b), suggesting an increased RVM descending serotonergic drive during this chronic pain condition. This may lead to overactivation of spinal 5-HT<sub>3</sub>R,

which, taking into account the pain facilitatory role here reported, is likely to contribute to mechanical hypersensitivity associated to DNP. No differences were observed in the spinal expression of 5-HT<sub>3</sub>RA in STZ-diabetic rats, which reinforces the hypothesis that 5-HT<sub>3</sub>R-mediated pain facilitation during DNP is likely to be caused by increased serotonin bioavailability rather than due to changes in the expression of the receptor. Studies also showed unaltered 5-HT<sub>3</sub>R expression in other chronic pain conditions (Rahman et al., 2009). Our findings along with the lack of antinociceptive effect of a 5-HT<sub>3</sub>R antagonist in an animal model of traumatic neuropathy, where increased descending serotonergic drive was not verified (Peters et al., 2010), clearly point to the important role of enhanced activity of descending serotonergic pathways in spinal 5-HT<sub>3</sub>R pain facilitation during DNP.

Increasing evidences show that extracellular signal-regulated kinases 1 and 2 (ERK1/2) expressed in the spinal cord are involved in nociceptive processing and spinal sensitization (Gao and Ji, 2009; Han et al., 2011). In fact, ERK1/2 are strongly activated in the spinal dorsal horn following peripheral inflammation and tissue/nerve injury and the pharmacological blockade of this activation reduces the hypersensitivity otherwise observed in these experimental models (Ji et al., 1999; 2002). This activation of ERKs has been attributed to the hyperexcitability of spinal dorsal horn neurons evoked by increased peripheral barrage. This assertion, while reasonable, discards the possible contribution of other dorsal horn inputs that are believed to regulate dorsal horn excitability, namely the inputs arising from descending modulatory pathways. Increased activation of ERK1/2 in STZ-diabetic rats was observed in the present study, in agreement with data from a previous study (Daulhac et al., 2006). In addition, our findings demonstrate that the i.t. administration of 5-HT<sub>3</sub>R antagonist reverted the increased spinal ERK1/2 activation in STZ-diabetic rats, pointing for a role of 5-HT<sub>3</sub>R-mediated descending serotonergic facilitation in spinal sensitization during DNP. Consistent with our data, previous studies demonstrated that the depletion of spinal 5-HT reduced the formalin evoked flinching and activation of spinal ERK1/2 pathways (Svensson et al., 2006). Moreover, intrathecal administration of ondansetron (a 5-HT<sub>3</sub> receptor antagonist) at doses that inhibited formalin-induced flinching also attenuated spinal ERK activation

(Svensson et al., 2006). Taken together these findings revealed that spinal ERKs activation requires the input from an excitatory serotonergic pathway and is dependent on 5HT3R activity.

At the spinal cord, 5-HT3R expression seems to be restricted to some neuronal subpopulations and primary afferents terminals (Kia et al., 1995), with no reported expression in glial cells (Guo et al., 2014). The mechanisms underlying 5-HT3R-mediated spinal pain modulation remain elusive. Recently, a 5-HT3R-dependent neuronal-glia crosstalk was proposed as a possible mechanism underlying pain facilitation induced by the pharmacological activation of spinal 5-HT3R in healthy animals (Guo et al., 2014), with an i.t. injection of 5-HT3R agonist leading to increased activation of microglia and astroglia and the reversion of these effect by treatment with a 5-HT3R specific antagonist. In the present study no differences were detected in the activation of spinal microglia or astroglia upon i.t. administration of 5-HT3R antagonist in STZ-diabetic rats. Our results do not seem to support a role for glia in the pronociceptive effects of spinal 5-HT3R, at least in this chronic pain condition. Indeed, it is important to note that Guo et al. (2014) studied the role of glial cells in the effects of spinal 5-HT3R activation in an acute pain condition and no reports exist on the effects of chronic pain in this mechanism. In the present study we used an animal model of chronic pain that already presents altered spinal glial responses before i.t. administration of 5-HT3R antagonist (Daulhac et al., 2006; Tsuda et al., 2008; Wodarski et al., 2009; Morgado et al., 2011a). The absence of a normal functioning of glia signalling cascade during DNP can contribute to the lack of effects of 5-HT3R on glia activation here reported.

The interplay between 5-HT and GABA was shown to be crucial in spinal modulation of nociceptive transmission. The electrical stimulation of RVM neurons elicits GABA-mediated inhibitory post-synaptic potentials (IPSPs) in primate spinothalamic tract neurons (Giesler et al., 1981). Furthermore, the GABA<sub>A</sub>-R agonist, muscimol, and 2-methyl 5-HT, a non-selective 5-HTR agonist, was shown to have similar effects on nociceptive spinal projection neurons firing elicited by excitatory amino acids (Lei and Wilcox, 1990). More recently, 5-HT3R expression was reported in an intrinsic GABAergic neuronal subpopulation of the spinal cord, and its activation on

these neurons was shown to enhance GABA release (Fukushima et al., 2009). This enhancement is likely to activate postsynaptic GABA<sub>A</sub>R, which was shown to culminate in antinociception by inhibiting spinothalamic tract ascending neurons (Alhaider et al., 1991; Kawamata et al., 2003). If in normal conditions GABA seems to play a major inhibitory tone on spinal nociceptive transmission, several studies have been showing that persistent pain conditions, including DNP, are accompanied by a shift in the role of GABA from inhibitory to excitatory, due to the decrease of spinal potassium chloride co-transporter 2 (KCC2) expression (Jolivalt et al., 2008; Morgado et al., 2008). The KCC2 downregulation promotes an accumulation of intracellular chloride which causes an outflow of chloride ions upon the binding of GABA to GABA<sub>A</sub>R, leading to neuronal excitation instead of inhibition and contributing to the spinal nociceptive hyperactivity observed in DNP (Morgado et al., 2011a). Our results show that the antinociceptive effects of i.t. administered 5-HT<sub>3</sub>R antagonist is abolished by i.t. delivery of muscimol, suggesting that the effects elicited by 5-HT<sub>3</sub>R antagonism are mediated by the reduction of GABA<sub>A</sub>R activation, probably due to a decrease in spinal GABA release.

In conclusion, the data gathered by the present study suggest that 5-HT<sub>3</sub>R-mediated increase in spinal GABAergic transmission, probably due to the overactivation of descending serotonergic pathways, can mediate pain facilitation during DNP. This study provides new insights on the mechanisms underlying the contribution of spinal 5-HT<sub>3</sub>R to pain modulation during chronic pain. Accordingly, and attending to the already reported good tolerability and pharmacokinetic profile of 5-HT<sub>3</sub>R inhibitory drugs in the clinical practice (McCleane et al., 2003), the use of 5-HT<sub>3</sub>R antagonists may then be considered as a promising pharmacological approach in alleviating the mechanical hyperalgesia associated to diabetic neuropathy.

### **Author contributions**

All authors participate in experimental conception and design. C. Morgado and I. Tavares supervised the experiments. M. Silva performed all the surgeries and behavioural tests. M. Silva and D. Martins performed

immunohistochemistry and western blot experiments. All authors discussed the results. M. Silva and D. Martins wrote the first drafts of the manuscript. C. Morgado and I. Tavares revised the manuscript. All authors have read and approved the final manuscript.

## References

Alhaider, A. A., Lei, S. Z., and Wilcox, G. L. (1991). Spinal 5HT, Receptor-mediated Antinociception: Possible Release of GABA. *The Journal of Neuroscience* 11, 1881–1888.

Brahmachari, S., Fung, Y. K., and Pahan, K. (2006). Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide. *The Journal of Neuroscience* 26, 4930–4939.

Burchiel, K. J., Russell, L. C., Lee, R. P., and Sima, A. A. F. (1985). Spontaneous Activity of Primary Afferent Neurons in Diabetic BB/Wistar Rats. A Possible Mechanism of Chronic Diabetic Neuropathic Pain. *Diabetes* 34, 1210–1213.

Calcutt, N. A. (2004). Modeling Diabetic Sensory Neuropathy in Rats. In *Methods in Molecular Medicine, Vol 99: Pain Research: Methods and Protocols*, Z. D. Luo, ed. (Humana Press Inc) pp. 1–12.

Chen, S.-R., and Pan, H.-L. (2002). Hypersensitivity of Spinothalamic Tract Neurons Associated With Diabetic Neuropathic Pain in Rats. *Journal of Neurophysiology* 87, 2726–2733.

Chen, X., and Levine, J. D. (2001). Hyper-responsivity in a subset of C-fiber nociceptors in a model of painful diabetic neuropathy in the rat. *Neuroscience* 102, 185–192.

Courteix, C., Eschalier, A., and Lavarenne, J. (1993). Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. *PAIN* 53, 81–88.

Daulhac, L., Mallet, C., Courteix, C., Etienne, M., Duroux, E., Privat, A. M., Eschalier, A., and Fialip, J. (2006). Diabetes-Induced Mechanical Hyperalgesia Involves Spinal Mitogen-Activated Protein Kinase Activation in Neurons and Microglia via N-Methyl-D-aspartate-Dependent Mechanisms. *Molecular Pharmacology* 70, 1246–1254.

Dogrul, A., Ossipov, M. H., and Porreca, F. (2009). Differential mediation of descending pain facilitation and inhibition by spinal 5HT-3 and 5HT-7 receptors. *Brain Research* 1280, 52–59.

Fei, Z., Bera, T. K., Liu, X., Xiang, L., and Pastan, I. (2011). Ankrd26 gene disruption enhances adipogenesis of mouse embryonic fibroblasts. *J Biol Chem* 286, 27761–27768.

Fukushima, T., Ohtsubo, T., Tsuda, M., Yanagawa, Y., and Hori, Y. (2009). Facilitatory Actions of Serotonin Type 3 Receptors on GABAergic Inhibitory Synaptic Transmission in the Spinal Superficial Dorsal Horn. *Journal of Neurophysiology* 102, 1459–1471.

Galer, B. S., Gianas, A., and Jensen, M. P. (2000). Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. *Diabetes Research and Clinical Practice* 47, 123–128.

Gao, Y.-J., and Ji, R.-R. (2009). c-Fos or pERK, Which is a Better Marker for Neuronal Activation and Central Sensitization After Noxious Stimulation and Tissue Injury? *TOPAINJ* 2, 11–17.

Giesler, G. S., Gerhart, K. D., Yeziarski, R. P., Wilcox, T. K., and Willis, W. D. (1981). Postsynaptic inhibition of primate spinothalamic neurons by stimulation in nucleus raphe magnus. *Brain Research* 204, 184–188.

Glaum, S. R., Proudfit, H. K., and Anderson, E. G. (1990). 5-HT<sub>3</sub> receptors modulate spinal nociceptive reflexes. *Brain Research* 510, 12–16.

Guo, W., Miyoshi, K., Dubner, R., Gu, M., Li, M., Liu, J., Yang, J., Zou, S., Ren, K., Noguchi, K., et al. (2014). Spinal 5-HT<sub>3</sub> receptors mediate descending facilitation and contribute to behavioral hypersensitivity via a reciprocal neuron-glia signaling cascade. *Molecular Pain* 10, 35.

Han, M., Huang, R.-Y., Du, Y.-M., Zhao, Z.-Q., and Zhang, Y.-Q. (2011). Early intervention of ERK activation in the spinal cord can block initiation of peripheral nerve injury-induced neuropathic pain in rats. *Sheng Li Xue Bao* 63, 106–114.

Hwang, J. H., and Yaksh, T. L. (1997). The effect of spinal GABA receptor agonists on tactile allodynia in a surgically-induced neuropathic pain model in the rat. *PAIN* 70, 15–22.

Ji, R. R., Baba, H., Brenner, G. J., and Woolf, C. J. (1999). Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. *Nat Neurosci* 2, 1114–1119.

Ji, R.-R., Befort, K., Brenner, G. J., and Woolf, C. J. (2002). ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity. *The Journal of Neuroscience* 22, 478–485.

- Jolivalt, C. G., Lee, C. A., Ramos, K. M., and Calcutt, N. A. (2008). Allodynia and hyperalgesia in diabetic rats are mediated by GABA and depletion of spinal potassium-chloride co-transporters. *PAIN* 140, 48–57.
- Kanazawa, A., Sawa, T., Akaike, T., and Maeda, H. (2002). Dietary lipid peroxidation products and DNA damage in colon carcinogenesis. *Eur. J. Lipid Sci. Technol.* 104, 439–447.
- Kaur, J., and Tikoo, K. (2013). p300/CBP dependent hyperacetylation of histone potentiates anticancer activity of gefitinib nanoparticles. *Biochim Biophys Acta* 1833, 1028–1040.
- Kawamata, T., Omote, K., Toriyabe, M., Yamamoto, H., and Namiki, A. (2003). The activation of 5-HT<sub>3</sub> receptors evokes GABA release in the spinal cord. *Brain Research* 978, 1–6.
- Kia, H. K., Miquel, M. C., McKernan, R. M., Laporte, A. M., Lombard, M. C., Bourgoin, S., Hamon, M., and Verge, D. (1995). Localization of 5-HT<sub>3</sub> receptors in the rat spinal cord: immunohistochemistry and in situ hybridization. *NeuroReport* 6, 257–261.
- Kim, Y. S., Chu, Y., Han, L., Li, M., Li, Z., LaVinka, P. C., Sun, S., Tang, Z., Park, K., Caterina, M. J., et al. (2014). Central Terminal Sensitization of TRPV1 by Descending Serotonergic Facilitation Modulates Chronic Pain. *Neuron*, 1–15.
- Lei, S., and Wilcox, G. L. (1990). Excitatory amino acid and opioid receptor regulation of spinal nociceptive neurotransmission. *European Journal of Pharmacology* 183, 1438–1439.
- Li, J.-Q., Chen, S.-R., Chen, H., Cai, Y.-Q., and Pan, H.-L. (2010). Regulation of increased glutamatergic input to spinal dorsal horn neurons by mGluR5 in diabetic neuropathic pain. *J Neurochem* 112, 162–172.
- McCleane, G. J., Suzuki, R., and Dickenson, A. H. (2003). Does a single intravenous injection of the 5HT<sub>3</sub> receptor antagonist ondansetron have an analgesic effect in neuropathic pain? A double-blinded, placebo-controlled cross-over study. *Anesth Analg* 97, 1474–1478.
- Morgado, C., and Tavares, I. (2007). C-fos expression at the spinal dorsal horn of streptozotocin-induced diabetic rats. *Diabetes Metab. Res. Rev.* 23, 644–652.
- Morgado, C., Pereira-Terra, P., Cruz, C. D., and Tavares, I. (2011a). Minocycline completely reverses mechanical hyperalgesia in diabetic rats through microglia-induced changes in the expression of the potassium

chloride co-transporter 2 (KCC2) at the spinal cord. *Diabetes, Obesity and Metabolism* 13, 150–159.

Morgado, C., Pinto-Ribeiro, F., and Tavares, I. (2008). Diabetes affects the expression of GABA and potassium chloride cotransporter in the spinal cord: A study in streptozotocin diabetic rats. *Neuroscience Letters* 438, 102–106.

Morgado, C., Silva, L., Pereira-Terra, P., and Tavares, I. (2011b). Changes in serotonergic and noradrenergic descending pain pathways during painful diabetic neuropathy: The preventive action of IGF1. *Neurobiology of Disease* 43, 275–284.

Morgado, C., Terra, P. P., and Tavares, I. (2010). Neuronal hyperactivity at the spinal cord and periaqueductal grey during painful diabetic neuropathy: Effects of gabapentin. *European Journal of Pain* 14, 693–699.

Ohsawa, K., Imai, Y., Sasaki, Y., and Kohsaka, S. (2004). Microglia/macrophage-specific protein Iba1 binds to fimbrin and enhances its actin-bundling activity. *J Neurochem* 88, 844–856.

Oyama, T., Ueda, M., Kuraishi, Y., Akaike, A., and Satoh, M. (1996). Dual effect of serotonin on formalin-induced nociception in the rat spinal cord. *Neuroscience Research* 25, 129–135.

Paulson, P. E., Wiley, J. W., and Morrow, T. J. (2007). Concurrent Activation of the Somatosensory Forebrain and Deactivation of Periaqueductal Grey Associated With Diabetes- Induced Neuropathic Pain. *Experimental Neurology* 208, 305–313.

Paxinos, G., and Watson, C. (2007). *The Rat Brain in Stereotaxic Coordinates*. 6 ed. Elsevier.

Pertovaara, A., Wei, H., Kalmari, J., and Ruotsalainen, M. (2001). Pain Behavior and Response Properties of Spinal Dorsal Horn Neurons Following Experimental Diabetic Neuropathy in the Rat: Modulation by Nitecapone, a COMT Inhibitor with Antioxidant Properties. *Experimental Neurology* 167, 425–434.

Peters, C. M., Hayashida, K.-I., Ewan, E. E., Nakajima, K., Obata, H., Xu, Q., Yaksh, T. L., and Eisenach, J. C. (2010). Lack of analgesic efficacy of spinal ondansetron on thermal and mechanical hypersensitivity following spinal nerve ligation in the rat. *Brain Research* 1352, 83–93.

Rahman, W., Bauer, C. S., Bannister, K., Vonsy, J.-L., Dolphin, A. C., and Dickenson, A. H. (2009). Descending serotonergic facilitation and the antinociceptive effects of pregabalin in a rat model of osteoarthritic pain.

*Molecular Pain* 5, 45.

Ralph, E., Boye, E., and Kearsey, S. E. (2006). DNA damage induces Cdt1 proteolysis in fission yeast through a pathway dependent on Cdt2 and Ddb1. *EMBO reports* 7, 1134–1139.

Silva, M., Amorim, D., Almeida, A., Tavares, I., Pinto-Ribeiro, F., and Morgado, C. (2013). Pronociceptive changes in the activity of rostroventromedial medulla (RVM) pain modulatory cells in the streptozotocin-diabetic rat. *Brain Research Bulletin* 96, 39–44.

Suzuki, R., Morcuende, S., Webber, M., Hunt, S. P., and Dickenson, A. H. (2002). Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways. *Nat Neurosci* 5, 1319–1326.

Svensson, C. I., Tran, T. K., Fitzsimmons, B., Yaksh, T. L., and Hua, X.-Y. (2006). Descending serotonergic facilitation of spinal ERK activation and pain behavior. *FEBS Letters* 580, 6629–6634.

Tsuda, M., Ueno, H., Kataoka, A., Tozaki-Saitoh, H., and Inoue, K. (2008). Activation of dorsal horn microglia contributes to diabetes-induced tactile allodynia via extracellular signal-regulated protein kinase signaling. *Glia* 56, 378–386.

Uslu, K., Coleman, A. S., Allman, W. R., Katsenelson, N., Bram, R. J., Alugupalli, K. R., and Akkoyunlu, M. (2014). Impaired B cell receptor signaling is responsible for reduced TACI expression and function in X-linked immunodeficient mice. *J Immunol* 192, 3582–3595.

Wang, Y. F., and Hatton, G. I. (2009). Astrocytic Plasticity and Patterned Oxytocin Neuronal Activity: Dynamic Interactions. *Journal of Neuroscience* 29, 1743–1754.

Wodarski, R., Clark, A. K., Grist, J., Marchand, F., and Malcangio, M. (2009). Gabapentin reverses microglial activation in the spinal cord of streptozotocin-induced diabetic rats. *European Journal of Pain* 13, 807–811.

Zeitz, K. P., Guy, N., Malmberg, A. B., Dirajlal, S., Martin, W. J., Sun, L., Bonhaus, D. W., Stucky, C. L., Julius, D., and Basbaum, A. I. (2002). Subtype of Serotonin Receptor Contributes to Nociceptive Processing via a Novel Subset of Myelinated and Unmyelinated Nociceptors. *The Journal of Neuroscience*, 1010–1019.

Zimmermann, M. (1983). Ethical guidelines for investigations of experimental pain in conscious animals. *PAIN* 16, 109–110.

## Legends

**Figure 1** - Effects of intrathecal administration of 5-HT<sub>3</sub>R antagonist on mechanical nociception. \*Control (saline and Y25130) vs STZ-diabetic (Saline and Y25130); # STZ+ Saline vs all other groups; two symbols  $p < 0.01$ , three symbols  $p < 0.001$ , four symbols  $p < 0.0001$ , by Two-Way ANOVA repeated measures followed by Tukey *post-hoc* test for multiple comparisons.

**Figure 2** – Effects of intrathecal administration of 5-HT<sub>3</sub>R antagonist on spinal ERK1/2 activation. (a) Number of pERK1/2-labeled cells in lamina I-V in sections from L4-L5 spinal segments; (b) quantification by western blotting of pERK1/2 expression in the L4 – L5 spinal cord homogenates and representative blots; (c-f) representative photomicrographs of sections from spinal segments L4-L5 immunoreacted against pERK1/2 in Control+Saline (c), Control+Y25130 (d), STZ+Saline (e) and STZ+Y25130 (f). (e') Representative photomicrograph of high magnification of pERK1/2-labeled cells in lamina I-II of L4 spinal segment from STZ+saline rats. Scale bar in f = 500 $\mu$ m, scale bar in e' = 200 $\mu$ m. #STZ+saline vs control groups; \*STZ+saline vs STZ+Y25130; one symbol  $p < 0.05$ , two symbols  $p < 0.01$ , by One-Way ANOVA followed by Tukey *post-hoc* test for multiple comparisons.

**Figure 3** – Effects of intrathecal muscimol in the antinociception elicited by the inhibition of spinal 5-HT<sub>3</sub>R on STZ-diabetic rat. \* STZ+Y25130 vs all other groups; three symbols  $p < 0.001$  by One-Way ANOVA followed by Tukey *post-hoc* test for multiple comparisons.

**Table S1** - Blood glucose concentration, percentage of hemoglobin A1C and body weights of STZ-diabetic and control animals.

**Figure S1** – Effects on intrathecal administration of 5-HT<sub>3</sub>R antagonist on the spinal expression levels of GFAP and IBA-1. (a) Quantification by western blotting of GFAP expression in the L4 – L5 spinal cord homogenates and representative blots; (b) quantification by western blotting of IBA-1 expression in the L4 – L5 spinal cord homogenates and representative blots. \* Control vs

STZ groups; two symbols  $p < 0.01$ , by One-Way ANOVA followed by Tukey *post-hoc* test for multiple comparisons.

**Figure S2** – Analysis of 5-HT<sub>3</sub>R subunit A (5-HT<sub>3</sub>RA) expression. (a) Immunolabelling optical density in lamina I-V for 5-HT<sub>3</sub>RA; (b) quantification by western blotting of 5-HT<sub>3</sub>RA expression in the L4 – L5 spinal cord homogenates and representative blots; (c-f) representative photomicrographs of sections from spinal segments L4-L5 immunoreacted against 5-HT<sub>3</sub>RA in Control+Saline (c), Control+Y25130 (d), STZ+Saline (e) and STZ+Y25130 (f). Scale bar: 500 $\mu$ m.

# Figures

Figure 1.




Figure 2.





Figure 3.



**Table S1** - Blood glucose concentration, percentage of hemoglobin A1C and body weights of STZ-diabetic and control animals.

Parameters	STZ	Control
Blood Glucose concentration (mg/dl)	512.9 ± 10.15 <sup>a</sup>	121.3 ± 7.36
Hemoglobin A1C (%)	12.1 ± 0.25 <sup>a</sup>	4.8 ± 0.06
Body weight (g)	261.5 ± 6.55 <sup>a</sup>	402.1 ± 5.98

Independent sample t test. <sup>a</sup>p < 0.0001.

Figure S1.





Figure S2.



# **ANEXOS**

## **ANEXO 1 - Authors Guidelines (European Journal of Pain)**

### **Manuscript Structure and Word Count**

#### 1) Manuscript

- Title page (see further details below)
- Abstract (should not exceed 250 words, see further details below)
- Text
  - o Introduction (no subheadings, should not exceed 500 words)
  - o Methods (or Literature Search Methods for Review Articles)
  - o Results
  - o Discussion and conclusions (should not exceed 1500 words)
- Acknowledgements
- Author contributions (see Section 6)
- References (limited to 80 for original manuscripts)
- Legends for illustrations and tables

#### 2) Tables (to be uploaded as separate files)

#### 3) Figures (to be uploaded as separate files)

#### 4) Supporting material (additional material that will be published online-only, to be uploaded separately, see further details below)

### **Title Page**

The title page should give:

- 1) The title of the article. Titles should be short and should not contain acronyms
- 2) A running head not exceeding 50 characters
- 3) The authors' names (initial(s) of first name(s) and last name of each author)
- 4) The names of the institutions at which the research was conducted, clearly linked to respective authors
- 5) The name, address, telephone and fax numbers, and e-mail address of the author responsible for correspondence
- 6) The category for which the manuscript is being submitted (original article, review, short communication)
- 7) A statement of all funding sources that supported the work
- 8) Any conflicts of interest disclosures (see Section 6).
- 9) Answers to each of the following questions in 2 or 3 bulleted statements (not exceeding 70 words): 'what's already known about this topic?' and 'what does this study add?'. For reviews only: 'database?' and ' what does this review add?'.

### **Abstract**

The abstract should not exceed 250 words and should describe the background, the aims, the methods, the results and the conclusions reached. It should contain only

standard abbreviations and no references. For Original Manuscripts the following subheadings are required:

- Background
- Methods
- Results
- Conclusions

For Reviews the following subheadings are required:

- Background and Objective
- Databases and Data Treatment
- Results
- Conclusions

### **Acknowledgements**

The acknowledgements section should specify acknowledgement of technical help, but no sources of financial and material support. These should be given in the "Funding Sources" on the Title page.

### **Author Contributions**

Authors are required to include a statement of responsibility at the end of their manuscript's text that specifies the contribution of every author (see Section 6). Please state that all authors discussed the results and commented on the manuscript.

### **References**

If you use, e.g., Reference Manager, please note that *EJP* has adapted its reference style to the reference style of the journal *Eur J Neuroscience*. If you use, e.g., EndNote, please note that *EJP* uses the same reference style as the journal *Neuron*. In the text: references should be cited in parentheses at the appropriate point in the text by author(s) and year in chronological order, e.g., (Mustola, 1996; Baer, 1997; Mustola and Baer, 1998; Mustola et al., 1999). If two or more references with the same first author and year are cited, use lower-case letters a, b, etc., after the year both in the text and in the reference list.

In the reference list: references to cited materials should be listed in alphabetical order at the end of the article. Please use Index Medicus abbreviations for journal titles. Include all authors. Do not use "et al." in the reference list.

Example for an article in a periodical:

De Peuter, S., Van Diest, I., Vansteenwegen, D. (2011). Understanding fear of pain in chronic pain: Interoceptive fear conditioning as a novel approach. *Eur J Pain* **15**,889–894.

Example for a chapter in a book:

Janes, R., Saarto, T. (2010). Oncologic therapy in cancer pain. In *Evidence-Based Chronic Pain Management*, C. Stannard, E. Kalso, J. Ballantyne, eds. (Oxford: Wiley-Blackwell) pp. 311–326.

Example for a book:

Van Zundert, J., Patijn, J., Hartrick, C. (2011). *Evidence-based Interventional Pain Practice* (Oxford: Wiley-Blackwell).

Citing and listing of Web references: As a minimum, the full URL should be given. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references should be listed separately (e.g., after the reference list) under the heading "Web references".

Personal communications, manuscripts in preparation and other unpublished data should not be cited in the reference list but may be mentioned in the text in parentheses.

## Figures

All colour illustrations will be published free of charge. All figures must be uploaded as separate files. Figure legends should be listed on a separate page in numerical order and should contain brief but comprehensible explanations.

Figures should be referred to in the text in numerical sequence as follows: Fig. 1, Figs 2–4. The place at which a figure is to be inserted in the printed text should be indicated clearly on a manuscript. Where a figure has more than one panel, each panel should be labeled in the top left-hand corner using lower case letters in parentheses i.e. '(a)', '(b)' etc., and a brief description of each panel given in the figure legend.

Authors are themselves responsible for obtaining permission to reproduce previously published figures or tables. When an individual is identifiable in a photograph written consent must be obtained. This permission must include the right to publish in electronic media.

Print publication requires high quality, EPS (lineart) or TIFF/PDF (halftone/photographs) files are preferable (though GIF, JPEG, PICT or Bitmap files are acceptable for submission). MS PowerPoint and Word Graphics are unsuitable for printed pictures. Scans (TIFF only) should have a resolution of 300 dpi (halftone) or 600 to 1200 dpi (line drawings) in relation to the reproduction size (see below). EPS files should be saved with fonts embedded (and with a TIFF preview if possible). For scanned images, the scanning resolution (at final image size) should

be as follows to ensure good reproduction: lineart: >600 dpi; half-tones: >300 dpi; figures containing both halftone and line images: >600 dpi.

Detailed instructions for electronic artwork preparation may be found at <http://authorservices.wiley.com/bauthor/illustration.asp>.

### **Tables**

Tables should be referred to in the text in numerical sequence as follows: Table 1, Table 2. Each table, with an appropriate brief legend, comprehensible without reference to the text, should be typed on a separate page. For footnotes, use superscripts 'a', 'b', 'c', etc., not asterisks or other symbols.

### **Supplementary Materials to be published online-only**

*EJP* encourages the submission of underlying data sets, appendices, additional figures or tables, movie files, animations, etc. as online-only supporting information. Supporting information should be uploaded during manuscript submission (see Section 3). Supporting information should be important ancillary information that is relevant to the parent article but which does not or cannot appear in the printed edition of the journal.

To submit any material to be published online only please do the following:

- choose the item "table" or "figure" as usual when uploading the files of tables or figures
- choose the item "manuscript" if you want to publish certain parts of the manuscript online only and upload the related word file
- scroll down the page and enter in the "description"-box the kind of material you want to submit online only.

Please use the following terms:

- for tables: "tableS1", "tableS2" etc.
- for figures: "figureS1", "figureS2" etc. The figure legends should be included in the figure's file.
- for parts of the manuscript's text: "methodsS1", "resultsS1", "discussionS1" or "AppendixS1" (please note that it is not possible to publish additional material for the introduction)
- please indicate and cite clearly in your manuscript the online only material using the terms given above.

### **Units & Abbreviations**

Measurements of length, height and volume should be reported in metric units (metre, kilogram, litre). Temperatures should be given in degrees Celsius and blood pressures in millimetres of mercury or kPa with the alternative units in parentheses. All other measurements including laboratory measurements should be reported in the metric system in terms of the International System of Units (SI).

Abbreviations should be limited and defined after the first use of the term.

### **Drug Names**

Generic names of drugs should be used where possible. When quoting from specific materials on proprietary drugs, authors must state in parentheses the name and address of the manufacturer.

